Cisplatin Resistance and HER-2 Expression in Ovarian Cancer Cells
Author Information
Author(s): C Marth, M Widschwendter, J Karn, N-P J0rgensen, G Windbichler, AG Zeimet, C Trop, G Daxenbichler
Primary Institution: University Hospital, Innsbruck, Austria; The Norwegian Radiumhospital, Oslo, Norway
Hypothesis
Can interferon-y prevent the development of cisplatin resistance in ovarian carcinoma cells?
Conclusion
Interferon-y treatment did not prevent the development of cisplatin resistance in ovarian carcinoma cells, which instead showed increased HER-2 expression.
Supporting Evidence
- Both cisplatin-resistant cell lines expressed HER-2 at higher levels than the wild-type cells.
- Interferon-y treatment increased the expression of tumor-associated antigens in all cell lines.
- Cisplatin resistance was associated with increased HER-2 protein and RNA levels.
Takeaway
The study found that using interferon-y with cisplatin didn't stop cancer cells from becoming resistant to the drug, and these resistant cells had more of a protein called HER-2.
Methodology
The study involved treating ovarian carcinoma cell lines with cisplatin and interferon-y over 8 months to assess resistance and HER-2 expression.
Limitations
The study was conducted in vitro, which may not fully replicate in vivo conditions.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website